Huvepharma Italia srl has developed its own technology for the production of Dalbavancin
Huvepharma Italia srl has developed its own technology for the production of the active ingredient Dalbavancin.
Dalbavancin is a second generation semi-synthetic lipoglycopeptide antibiotic indicated in adults for the treatment of acute bacterial infections of the skin and skin structure.
The procedure has begun to obtain approval from the competent authorities for the production of Dalbavancin.
Approval for the manufacturing in GMP is expected by the end of 2022.
The production of Dalbavancin will take place at the Garessio plant of Huvepharma Italia srl.
The expected analytical characteristics of Dalbavancin are now available, as well as small quantities of product samples, necessary for building future commercial partnerships.
The CEO of the Huvepharma Italia S.r.l., Mr. Nicola De Risi, commented that the production of Dalbavancin in addition to expanding the product list for the benefit of its partners, also represents a significant leap in quality in terms of pharmaceutical technology for the Garessio plant, because for the first time in its very long history, it will be produced an active ingredient for injectable use.